SEATTLE, June 22, 2018 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S.
Growth Capitalist (https://growthcapitalist.com/2018/06/impel-neuropharma-announces-fda-clearance-of-ind-for-pivotal-phase-3-study-of-inp104-for-acute-treatment-of-migraine/)
SEATTLE, June 22, 2018 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S.